Early Detection and Staging of Adenocarcinoma of the Pancreas

Gastroenterology Clinics of North America

Volumn 36, Issue 2, 2007, Pages 413-429

  Pappas, Sam ^a   Federle, Michael P ^b   Lokshin, Anna E ^a   Zeh III, Herbert J ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HIGH RISK POPULATION; HUMAN; LAPAROSCOPY; LAPAROTOMY; LYMPH NODE; MULTIDETECTOR COMPUTED TOMOGRAPHY; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PATIENT CARE; PATIENT CODING; POSITRON EMISSION TOMOGRAPHY; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; BIOPSY, FINE-NEEDLE; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; ENDOSONOGRAPHY; HUMANS; LAPAROSCOPY; NEOPLASM STAGING; PANCREATIC NEOPLASMS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34249307516     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2007.03.013     Document Type: Review

References (78)

1. Etzioni R., Urban N., Ramsey S., et al. The case for early detection. Nat Rev Cancer 3 4 (2003) 243-252
2. Sohn T.A., Yeo C.J., Cameron J.L., et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4 6 (2000) 567-579
3. Ariyama J., Suyama M., Ogawa K., et al. The detection and prognosis of small pancreatic carcinoma. Int J Pancreatol 7 1-3 (1990) 37-47
4. Breslin T.M., Hess K.R., Harbison D.B., et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8 2 (2001) 123-132
5. Wayne J.D., Abdalla E.K., Wolff R.A., et al. Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. Oncologist 7 1 (2002) 34-45
6. Varadhachary G.R., Tamm E.P., Abbruzzese J.L., et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13 8 (2006) 1035-1046
7. Crane C.H., Varadhachary G., Wolff R.A., et al. The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. Best Pract Res Clin Gastroenterol 20 2 (2006) 365-382
8. Kern S. A white paper: the product of a pancreas cancer think tank. Cancer Res 2001;61(12):4923-32.
9. Brune K., Abe T., Canto M., et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 30 9 (2006) 1067-1076
10. Canto M.I., Goggins M., Hruban R.H., et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4 6 (2006) 766-781
11. Brentnall T.A. Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options Oncol 6 5 (2005) 437-445
12. Rulyak S.J., Kimmey M.B., Veenstra D.L., et al. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 57 1 (2003) 23-29
13. Rulyak S.J., and Brentnall T.A. Inherited pancreatic cancer: surveillance and treatment strategies for affected families. Pancreatology 1 5 (2001) 477-485
14. Rulyak S.J., Lowenfels A.B., Maisonneuve P., et al. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 124 5 (2003) 1292-1299
15. Levy M.J. Screening for pancreatic cancer: searching for the right needle in the haystack. Clin Gastroenterol Hepatol 4 6 (2006) 684-687
16. Kim H.J., Kim M.H., Myung S.J., et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 94 7 (1999) 1941-1946
17. Slesak B., Harlozinska-Szmyrka A., Knast W., et al. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9. Cancer 89 1 (2000) 83-88
18. Zhou W., Sokoll L.J., Bruzek D.J., et al. Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers Prev 7 2 (1998) 109-112
19. Koopmann J., Rosenzweig C.N., Zhang Z., et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 12 2 (2006) 442-446
20. Argani P., Iacobuzio-Donahue C., Ryu B., et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7 12 (2001) 3862-3868
21. Eskelinen M., and Haglund U. Developments in serologic detection of human pancreatic adenocarcinoma. Scand J Gastroenterol 34 9 (1999) 833-844
22. Iacobuzio-Donahue C.A., Ryu B., Hruban R.H., et al. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol 160 1 (2002) 91-99
23. Sato N., Fukushima N., Maehara N., et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 22 32 (2003) 5021-5030
24. Hayakawa T., Naruse S., Kitagawa M., et al. A prospective multicenter trial evaluating diagnostic validity of multivariate analysis and individual serum marker in differential diagnosis of pancreatic cancer from benign pancreatic diseases. Int J Pancreatol 25 1 (1999) 23-29
25. Zeh H.J., Winikoff S., Landsittel D.P., et al. Multianalyte profiling of serum cytokines for detection of pancreatic cancer. Cancer Biomark 1 6 (2005) 259-269
26. Koopmann J., Zhang Z., White N., et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 10 3 (2004) 860-868
27. Hauskrecht M., Pelikan R., Malehorn D.E., et al. Feature selection for classification of SELDI-TOF-MS proteomic profiles. Appl Bioinformatics 4 4 (2005) 227-246
28. Yu Y., Chen S., Wang L.S., et al. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology 68 1 (2005) 79-86
29. Rosty C., and Goggins M. Identification of differentially expressed proteins in pancreatic cancer using a global proteomic approach. Methods Mol Med 103 (2005) 189-197
30. Sorenson G.D. A review of studies on the detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Ann N Y Acad Sci 906 (2000) 13-16
31. Puig P., Urgell E., Capella G., et al. A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer. Int J Cancer 85 1 (2000) 73-77
32. Puig P., Urgell E., Capella G., et al. Improved detection of K-ras codon 12 mutations in fecal exfoliated cells. Lab Invest 79 5 (1999) 617-618
33. Castells A., Puig P., Mora J., et al. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol 17 2 (1999) 578-584
34. Suwa H., Ohshio G., Okada N., et al. Clinical significance of serum p53 antigen in patients with pancreatic carcinomas. Gut 40 5 (1997) 647-653
35. van Heek T., Rader A.E., Offerhaus G.J., et al. K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis. Am J Clin Pathol 117 5 (2002) 755-765
36. Zambon C., Navaglia F., Basso D., et al. ME-PCR for the identification of mutated K-ras in serum and bile of pancreatic cancer patients: an unsatisfactory technique for clinical applications. Clin Chim Acta 302 1-2 (2000) 35-48
37. Pisters P.W., Evans D.B., Leung D.H., et al. Re: surgery for ductal adenocarcinoma of the pancreatic head. World J Surg 25 4 (2001) 533-534
38. Michl P., Pauls S., and Gress T.M. Evidence-based diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol 20 2 (2006) 227-251
39. Soriano A., Castells A., Ayuso C., et al. Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am J Gastroenterol 99 3 (2004) 492-501
40. Smith S.L., and Rajan P.S. Imaging of pancreatic adenocarcinoma with emphasis on multidetector CT. Clin Radiol 59 1 (2004) 26-38
41. Horton K.M., and Fishman E.K. Adenocarcinoma of the pancreas: CT imaging. Radiol Clin North Am 40 6 (2002) 1263-1272
42. Horton K.M., and Fishman E.K. Multidetector row CT with dual-phase CT angiography in the preoperative evaluation of pancreatic cancer. Crit Rev Comput Tomogr 43 5 (2002) 323-360
43. Johnson P.T., Heath D.G., Hofmann L.V., et al. Multidetector-row computed tomography with three-dimensional volume rendering of pancreatic cancer: a complete preoperative staging tool using computed tomography angiography and volume-rendered cholangiopancreatography. J Comput Assist Tomogr 27 3 (2003) 347-353
44. House M.G., Yeo C.J., Cameron J.L., et al. Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg 8 3 (2004) 280-288
45. Horton K.M., and Fishman E.K. 3D CT angiography of the celiac and superior mesenteric arteries with multidetector CT data sets: preliminary observations. Abdom Imaging 25 5 (2000) 523-525
46. Yasuda K., Mukai H., Fujimoto S., et al. The diagnosis of pancreatic cancer by endoscopic ultrasonography. Gastrointest Endosc 34 1 (1988) 1-8
47. Rosch T., Dittler H.J., Strobel K., et al. Endoscopic ultrasound criteria for vascular invasion in the staging of cancer of the head of the pancreas: a blind reevaluation of videotapes. Gastrointest Endosc 52 4 (2000) 469-477
48. Dewitt J., Devereaux B.M., Lehman G.A., et al. Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review. Clin Gastroenterol Hepatol 4 6 (2006) 717-725
49. Rosch T. Staging of pancreatic cancer. Analysis of literature results. Gastrointest Endosc Clin N Am 5 4 (1995) 735-739
50. Raut C.P., Grau A.M., Staerkel G.A., et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg 7 1 (2003) 118-126
51. Powis M.E., and Chang K.J. Endoscopic ultrasound in the clinical staging and management of pancreatic cancer: its impact on cost of treatment. Cancer Control 7 5 (2000) 413-420
52. Horwhat J.D., Paulson E.K., McGrath K., et al. A randomized comparison of EUS-guided FNA versus CT or US-guided FNA for the evaluation of pancreatic mass lesions. Gastrointest Endosc 63 7 (2006) 966-975
53. Delbeke D., Rose D.M., Chapman W.C., et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 40 11 (1999) 1784-1791
54. Rose D.M., Delbeke D., Beauchamp R.D., et al. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 229 5 (1999) 729-737
55. Pakzad F., Groves A.M., and Ell P.J. The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 36 3 (2006) 248-256
56. Maemura K., Takao S., Shinchi H., et al. Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer. J Hepatobiliary Pancreat Surg 13 5 (2006) 435-441
57. Maisey N.R., Webb A., Flux G.D., et al. FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer 83 3 (2000) 287-293
58. Bang S., Chung H.W., Park S.W., et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 40 10 (2006) 923-929
59. Lemke A.J., Niehues S.M., Hosten N., et al. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions-a prospective study with 104 patients. J Nucl Med 45 8 (2004) 1279-1286
60. Heinrich S., Goerres G.W., Schafer M., et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 242 2 (2005) 235-243
61. Brugge W.R. Advances in the endoscopic management of patients with pancreatic and biliary malignancies. South Med J 99 12 (2006) 1358-1366
62. Kimmey M.B., Bronner M.P., Byrd D.R., et al. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 56 4 Suppl (2002) S82-S86
63. Balcom J.H., Fernandez-del Castillo C., and Warshaw A. Staging of adenocarcinoma of the pancreas. In: Cameron J.L. (Ed). Pancreatic cancer (2001), BC Decker Incorporated, Hamilton (Canada) 87-97
64. Jimenez R.E., Warshaw A.L., and Fernandez-Del C.C. Laparoscopy and peritoneal cytology in the staging of pancreatic cancer. J Hepatobiliary Pancreat Surg 7 1 (2000) 15-20
65. Jimenez R.E., Warshaw A.L., Rattner D.W., et al. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg 135 4 (2000) 409-414
66. Shoup M., Winston C., Brennan M.F., et al. Is there a role for staging laparoscopy in patients with locally advanced, unresectable pancreatic adenocarcinoma?. J Gastrointest Surg 8 8 (2004) 1068-1071
67. Liu R.C., and Traverso L.W. Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography. Surg Endosc 19 5 (2005) 638-642
68. Pasanen P.A., Eskelinen M., Partanen K., et al. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy. Anticancer Res 15 6B (1995) 2731-2737
69. Pasquali C., Sperti C., D'Andrea A.A., et al. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9. Int J Pancreatol 15 3 (1994) 171-177
70. Nilsson O., Johansson C., Glimelius B., et al. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9. Br J Cancer 65 2 (1992) 215-221
71. Haglund C. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA. Br J Cancer 54 6 (1986) 897-901
72. Andicoechea A., Vizoso F., Alexandre E., et al. Comparative study of carbohydrate antigen 195 and carcinoembryonic antigen for the diagnosis of pancreatic carcinoma. World J Surg 23 3 (1999) 227-231
73. Frena A. SPan-1 and exocrine pancreatic carcinoma. The clinical role of a new tumor marker. Int J Biol Markers 16 3 (2001 Jul) 189-197
74. Karna E., Surazynski A., Orlowski K., et al. Serum and tissue level of insulin-like growth factor-I (IGF-I) and IGF-I binding proteins as an index of pancreatitis and pancreatic cancer. Int J Exp Pathol 83 5 (2002) 239-245
75. Ellenrieder V., Alber B., Lacher U., et al. Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer 85 1 (2000) 14-20
76. Kuwada Y., Sasaki T., Morinaka K., et al. Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. Int J Oncol 22 4 (2003) 765-771
77. Yamamoto H., Itoh F., Iku S., et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 19 4 (2001) 1118-1127
78. Argani P., Rosty C., Reiter R.E., et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 61 11 (2001) 4320-4324